Alzheimer's Disease
Conditions
Keywords
Dementia, Alzheimer Type Senile Dementia, Cognitive impairment
Brief summary
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.
Detailed description
Alzheimer's disease (AD) is a progressive and fatal neurological illness. It produces changes in the brain that include loss of cells and accumulation of abnormal protein deposits. Initial symptoms are cognitive, with deficiencies in short-term memory the most common symptom. As the disease progresses so does the severity of cognitive deficiency. Loss of speech and immobility occur in the terminal stages There is no cure for AD and no marketed treatment that modifies the underlying disease process. Available therapies improve some symptoms of AD by increasing brain concentrations of molecules involved in cognition. ST101 differs from marketed therapies in that it has demonstrated two actions in animal research testing. It improves cognition and it also reduces the accumulation of abnormal protein deposits in the brain. These two properties suggest that ST101 may be a promising agent for the treatment of AD. This study is designed as a preliminary dose exploration/proof-of-concept investigation of the ability of ST101 to improve cognition during 12 weeks of administration.
Interventions
DRUGST101
30 mg; administered once/day
DRUGPlacebo
placebo to match ST101 tablets
Sponsors
Sonexa Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnostic evidence of mild to moderate Alzheimer's disease. * CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology. * A reliable and capable caregiver.
Exclusion criteria
* Subjects who reside in a skilled nursing facility. * Subjects with B12 or folate deficiency. * Subjects with chronic hepatic disease. * Subjects with a recent history of hematologic/oncologic disorders. * Subjects who have experienced a myocardial infarction with the past year. * Dementia caused or complicated by other organic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog) | Baseline, 4 weeks, 8 weeks,12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Neuropsychiatric Inventory (NPI) | Baseline, 4 weeks, 8 weeks, 12 weeks |
| Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI) | Baseline (severity); 4 weeks, 8 weeks, 12 weeks (change) |
Countries
Canada, United States
Outcome results
None listed